Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

Clinical impact of genomic diversity from early to advanced hepatocellular carcinoma.

Nault JC, Martin Y, Caruso S, Hirsch TZ, Bayard Q, Calderaro J, Charpy C, Copie-Bergman C, Ziol M, Bioulac-Sage P, Couchy G, Blanc JF, Nahon P, Amaddeo G, Ganne-Carrie N, Morcrette G, Chiche L, Duvoux C, Faivre S, Laurent A, Imbeaud S, Rebouissou S, Llovet J, Seror O, Letouzé E, Zucman-Rossi J.

Hepatology. 2019 Jun 17. doi: 10.1002/hep.30811. [Epub ahead of print]

PMID:
31206197
2.

Multibipolar Radiofrequency Ablation for the Treatment of Mass-Forming and Infiltrative Hepatocellular Carcinomas > 5 cm: Long-Term Results.

N'Kontchou G, Nault JC, Sutter O, Bourcier V, Coderc E, Grando V, Nahon P, Ganne-Carrié N, Diallo A, Sellier N, Seror O.

Liver Cancer. 2019 May;8(3):172-185. doi: 10.1159/000489319. Epub 2018 Jun 28.

PMID:
31192154
3.

Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort.

Laurain A, Metivier S, Haour G, Larrey D, Dorival C, Hezode C, Zoulim F, Marcellin P, Bourliere M, Zarski JP, Thabut D, Alric L, Ganne-Carrie N, Cales P, Bronowicki JP, Riachi G, Geist C, Causse X, Abergel A, Chazouilleres O, Mathurin P, Guyader D, Samuel D, Tran A, Loustaud-Ratti V, Petrov-Sanchez V, Diallo A, Luzivika-Nzinga C, Fontaine H, Carrat F, Pol S; ANRS/AFEF HEPATHER study group.

BMC Infect Dis. 2019 Apr 2;19(1):300. doi: 10.1186/s12879-019-3923-5.

4.

A 17-Beta-Hydroxysteroid Dehydrogenase 13 Variant Protects From Hepatocellular Carcinoma Development in Alcoholic Liver Disease.

Yang J, Trépo E, Nahon P, Cao Q, Moreno C, Letouzé E, Imbeaud S, Bayard Q, Gustot T, Deviere J, Bioulac-Sage P, Calderaro J, Ganne-Carrié N, Laurent A, Blanc JF, Guyot E, Sutton A, Ziol M, Zucman-Rossi J, Nault JC.

Hepatology. 2019 Mar 25. doi: 10.1002/hep.30623. [Epub ahead of print]

PMID:
30908678
5.

Alcohol-related liver disease: do weather and daylight level matter or is there a paradoxical good side of global warming?

Ganne-Carrié N.

Transl Gastroenterol Hepatol. 2018 Dec 27;3:109. doi: 10.21037/tgh.2018.12.08. eCollection 2018. No abstract available.

6.

Hepatocellular carcinoma in the setting of alcohol-related liver disease.

Ganne-Carrié N, Nahon P.

J Hepatol. 2019 Feb;70(2):284-293. doi: 10.1016/j.jhep.2018.10.008. Review.

PMID:
30658729
7.

Non-virological factors are drivers of hepatocellular carcinoma in virosuppressed hepatitis B cirrhosis: Results of ANRS CO12 CirVir cohort.

Brichler S, Nahon P, Zoulim F, Layese R, Bourcier V, Audureau E, Sutton A, Letouze E, Cagnot C, Marcellin P, Guyader D, Roulot D, Pol S, de Ledinghen V, Zarski JP, Calès P, Tran A, Peron JM, Mallat A, Riachi G, Grange JD, Blanc JF, Bacq Y, Ouzan D, Bronowicki JP, Mathurin P, Larrey D, Alric L, Attali P, Serfaty L, Pilette C, Bourlière M, Thabut D, Silvain C, Wartelle C, Zucman D, Christidis C, Roudot-Thoraval F, Ganne-Carrie N; ANRS CO12 CirVir study group.

J Viral Hepat. 2019 Mar;26(3):384-396. doi: 10.1111/jvh.13029. Epub 2019 Jan 16.

PMID:
30380181
8.

PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases.

Yang J, Trépo E, Nahon P, Cao Q, Moreno C, Letouzé E, Imbeaud S, Gustot T, Deviere J, Debette S, Amouyel P, Bioulac-Sage P, Calderaro J, Ganne-Carrié N, Laurent A, Blanc JF, Guyot E, Sutton A, Ziol M, Zucman-Rossi J, Nault JC.

Int J Cancer. 2019 Feb 1;144(3):533-544. doi: 10.1002/ijc.31910. Epub 2018 Nov 9.

PMID:
30289982
9.

Virologic control and severity of liver disease determine survival after radiofrequency ablation of hepatocellular carcinoma on cirrhosis.

Allaire M, Rekik S, Layese R, Mumana A, Guyot E, Nkontchou G, Bourcier V, Grando V, Ziol M, Nahon P, Ganne-Carrié N, Sutter O, Audureau E, Seror O, Nault JC.

Dig Liver Dis. 2019 Jan;51(1):86-94. doi: 10.1016/j.dld.2018.07.014. Epub 2018 Jul 24.

PMID:
30126822
10.

Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis.

Ganne-Carrié N, Chaffaut C, Bourcier V, Archambeaud I, Perarnau JM, Oberti F, Roulot D, Moreno C, Louvet A, Dao T, Moirand R, Goria O, Nguyen-Khac E, Carbonell N, Antonini T, Pol S, de Ledinghen V, Ozenne V, Henrion J, Péron JM, Tran A, Perlemuter G, Amiot X, Zarski JP, Beaugrand M, Chevret S; for CIRRAL Group.

J Hepatol. 2018 Dec;69(6):1274-1283. doi: 10.1016/j.jhep.2018.07.022. Epub 2018 Aug 6.

11.

The epidemiology of Budd-Chiari syndrome in France.

Ollivier-Hourmand I, Allaire M, Goutte N, Morello R, Chagneau-Derrode C, Goria O, Dumortier J, Cervoni JP, Dharancy S, Ganne-Carrié N, Bureau C, Carbonell N, Abergel A, Nousbaum JB, Anty R, Barraud H, Ripault MP, De Ledinghen V, Minello A, Oberti F, Radenne S, Bendersky N, Farges O, Archambeaud I, Guillygomarc'h A, Ecochard M, Ozenne V, Hilleret MN, Nguyen-Khac E, Dauvois B, Perarnau JM, Lefilliatre P, Raabe JJ, Doffoel M, Becquart JP, Saillard E, Valla D, Dao T, Plessier A; French Network for Vascular Disorders of the Liver.

Dig Liver Dis. 2018 Sep;50(9):931-937. doi: 10.1016/j.dld.2018.04.004. Epub 2018 Apr 12.

PMID:
29803757
12.

Influence of Progenitor-Derived Regeneration Markers on Hepatitis C Virus-Related Cirrhosis Outcome (ANRS CO12 CirVir Cohort).

Wendum D, Layese R, Ganne-Carrié N, Bourcier V, Merabtene F, Cagnot C, Sauce E, Barget N, Bedossa P, Terris B, Selves J, Bioulac-Sage P, Sturm N, Sattonnet C, Nahon P, Roudot-Thoraval F, Ziol M; ANRS CO12 CirVir Group.

Hepatology. 2018 Oct;68(4):1534-1548. doi: 10.1002/hep.29927.

PMID:
29637581
13.

Positron emission tomography/computed tomography with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma.

Chalaye J, Costentin CE, Luciani A, Amaddeo G, Ganne-Carrié N, Baranes L, Allaire M, Calderaro J, Azoulay D, Nahon P, Seror O, Mallat A, Soussan M, Duvoux C, Itti E, Nault JC.

J Hepatol. 2018 Aug;69(2):336-344. doi: 10.1016/j.jhep.2018.02.018. Epub 2018 Mar 6.

PMID:
29518452
14.

Determination of candidate metabolite biomarkers associated with recurrence of HCV-related hepatocellular carcinoma.

Liu Z, Nahon P, Li Z, Yin P, Li Y, Amathieu R, Ganne-Carrié N, Ziol M, Sellier N, Seror O, Le Moyec L, Savarin P, Xu G.

Oncotarget. 2017 Dec 15;9(5):6245-6258. doi: 10.18632/oncotarget.23500. eCollection 2018 Jan 19.

15.

Eating Patterns in Patients with Compensated Cirrhosis: A Case-Control Study.

Buscail C, Bourcier V, Fezeu LK, Roulot D, Brulé S, Ben-Abdesselam Z, Cagnot C, Hercberg S, Nahon P, Ganne-Carrié N, Julia C.

Nutrients. 2018 Jan 10;10(1). pii: E60. doi: 10.3390/nu10010060.

16.

Macrotrabecular-massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance.

Ziol M, Poté N, Amaddeo G, Laurent A, Nault JC, Oberti F, Costentin C, Michalak S, Bouattour M, Francoz C, Pageaux GP, Ramos J, Decaens T, Luciani A, Guiu B, Vilgrain V, Aubé C, Derman J, Charpy C, Zucman-Rossi J, Barget N, Seror O, Ganne-Carrié N, Paradis V, Calderaro J.

Hepatology. 2018 Jul;68(1):103-112. doi: 10.1002/hep.29762. Epub 2018 May 9.

PMID:
29281854
17.

Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations.

Nault JC, Sutter O, Nahon P, Ganne-Carrié N, Séror O.

J Hepatol. 2018 Apr;68(4):783-797. doi: 10.1016/j.jhep.2017.10.004. Epub 2017 Oct 13. Review.

PMID:
29031662
18.

Cirrhosis: 10 key messages

Ganne-Carrié N.

Rev Prat. 2017 Sep;67(7):743. French. No abstract available.

PMID:
30512769
19.

Epidemiology of liver cirrhosis

Ganne-Carrié N.

Rev Prat. 2017 Sep;67(7):726-730. French.

PMID:
30512765
20.

[Care pathway of patients with hepatocellular carcinoma in France: State of play in 2017].

Costentin C, Ganne-Carrié N, Rousseau B, Gérolami R, Barbare JC.

Bull Cancer. 2017 Sep;104(9):752-761. doi: 10.1016/j.bulcan.2017.06.008. Epub 2017 Jul 24. Review. French.

PMID:
28751065
21.

[Screening of hepatocellular carcinoma in patients with uncomplicated cirrhosis in real life: Practices survey of general practionners from three towns of Seine-Saint-Denis (north-east suburb of Paris)].

Jiar N, Slama JL, Ganne-Carrié N.

Bull Cancer. 2017 Jul - Aug;104(7-8):618-624. doi: 10.1016/j.bulcan.2017.06.004. Epub 2017 Jul 5. French.

PMID:
28688744
22.

Sorafenib vs surgical resection for hepatocellular carcinoma with macrovascular invasion: A propensity score analysis.

Costentin CE, Decaens T, Laurent A, Nault JC, Paule B, Letoublon C, Luciani A, Calderaro J, Adam R, Bricault I, Amaddeo G, Cherqui D, Mallat A, Samuel D, Duvoux C, Ganne-Carrié N, Roudot-Thoraval F, Vibert E.

Liver Int. 2017 Dec;37(12):1869-1876. doi: 10.1111/liv.13491. Epub 2017 Jul 13.

PMID:
28609020
23.

Safety and Efficacy of Irreversible Electroporation for the Treatment of Hepatocellular Carcinoma Not Amenable to Thermal Ablation Techniques: A Retrospective Single-Center Case Series.

Sutter O, Calvo J, N'Kontchou G, Nault JC, Ourabia R, Nahon P, Ganne-Carrié N, Bourcier V, Zentar N, Bouhafs F, Sellier N, Diallo A, Seror O.

Radiology. 2017 Sep;284(3):877-886. doi: 10.1148/radiol.2017161413. Epub 2017 Apr 28.

PMID:
28453431
24.

Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.

Bourlière M, Rabiega P, Ganne-Carrie N, Serfaty L, Marcellin P, Barthe Y, Thabut D, Guyader D, Hezode C, Picon M, Causse X, Leroy V, Bronowicki JP, Carrieri P, Riachi G, Rosa I, Attali P, Molina JM, Bacq Y, Tran A, Grangé JD, Zoulim F, Fontaine H, Alric L, Bertucci I, Bouvier-Alias M, Carrat F; ANRS HB06 PEGAN Study Group.

Lancet Gastroenterol Hepatol. 2017 Mar;2(3):177-188. doi: 10.1016/S2468-1253(16)30189-3. Epub 2017 Jan 20.

PMID:
28404133
25.

Proliferation Markers Are Associated with MET Expression in Hepatocellular Carcinoma and Predict Tivantinib Sensitivity In Vitro.

Rebouissou S, La Bella T, Rekik S, Imbeaud S, Calatayud AL, Rohr-Udilova N, Martin Y, Couchy G, Bioulac-Sage P, Grasl-Kraupp B, de Koning L, Ganne-Carrié N, Nault JC, Ziol M, Zucman-Rossi J.

Clin Cancer Res. 2017 Aug 1;23(15):4364-4375. doi: 10.1158/1078-0432.CCR-16-3118. Epub 2017 Feb 28.

26.

Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.

van der Meer AJ, Feld JJ, Hofer H, Almasio PL, Calvaruso V, Fernández-Rodríguez CM, Aleman S, Ganne-Carrié N, D'Ambrosio R, Pol S, Trapero-Marugan M, Maan R, Moreno-Otero R, Mallet V, Hultcrantz R, Weiland O, Rutter K, Di Marco V, Alonso S, Bruno S, Colombo M, de Knegt RJ, Veldt BJ, Hansen BE, Janssen HLA.

J Hepatol. 2017 Mar;66(3):485-493. doi: 10.1016/j.jhep.2016.10.017. Epub 2016 Oct 22.

PMID:
27780714
27.

Hepatocellular Carcinoma within Milan Criteria: No-Touch Multibipolar Radiofrequency Ablation for Treatment-Long-term Results.

Seror O, N'Kontchou G, Nault JC, Rabahi Y, Nahon P, Ganne-Carrié N, Grando V, Zentar N, Beaugrand M, Trinchet JC, Diallo A, Sellier N.

Radiology. 2016 Sep;280(3):981. doi: 10.1148/radiol.2016164017. No abstract available.

PMID:
27533029
28.

BRIP1 coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV- or HBV-related liver disease.

Oussalah A, Avogbe PH, Guyot E, Chery C, Guéant-Rodriguez RM, Ganne-Carrié N, Cobat A, Moradpour D, Nalpas B, Negro F, Poynard T, Pol S, Bochud PY, Abel L, Jeulin H, Schvoerer E, Chabi N, Amouzou E, Sanni A, Barraud H, Rouyer P, Josse T, Goffinet L, Jouve JL, Minello A, Bonithon-Kopp C, Thiefin G, Di Martino V, Doffoël M, Richou C, Raab JJ, Hillon P, Bronowicki JP, Guéant JL; CiRCE Study Group.

Oncotarget. 2016 Aug 17;8(38):62842-62857. doi: 10.18632/oncotarget.11327. eCollection 2017 Sep 8.

29.

The CRP level and STATE score predict survival in cirrhotic patients with hepatocellular carcinoma treated by transarterial embolization.

Rekik S, Guyot E, Bhais M, Ajavon Y, Grando V, Bourcier V, Nkontchou G, Nahon P, Sellier N, Seror O, Ganne-Carrie N, Nault JC.

Dig Liver Dis. 2016 Sep;48(9):1088-92. doi: 10.1016/j.dld.2016.06.005. Epub 2016 Jun 15.

PMID:
27375209
30.

Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir).

Ganne-Carrié N, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, de Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Benhamou Y, Pilette C, Silvain C, Christidis C, Capron D, Bernard-Chabert B, Zucman D, Di Martino V, Trinchet JC, Nahon P, Roudot-Thoraval F; ANRS CO12 CirVir Study Group.

Hepatology. 2016 Oct;64(4):1136-47. doi: 10.1002/hep.28702. Epub 2016 Aug 4.

31.

Sequential Serum Metabolomic Profiling after Radiofrequency Ablation of Hepatocellular Carcinoma Reveals Different Response Patterns According to Etiology.

Goossens C, Nahon P, Le Moyec L, Triba MN, Bouchemal N, Amathieu R, Ganne-Carrié N, Ziol M, Trinchet JC, Sellier N, Diallo A, Seror O, Savarin P.

J Proteome Res. 2016 May 6;15(5):1446-54. doi: 10.1021/acs.jproteome.5b01032. Epub 2016 Apr 14.

PMID:
27015127
32.

Hepatocellular Carcinoma within Milan Criteria: No-Touch Multibipolar Radiofrequency Ablation for Treatment-Long-term Results.

Seror O, N'Kontchou G, Nault JC, Rabahi Y, Nahon P, Ganne-Carrié N, Grando V, Zentar N, Beaugrand M, Trinchet JC, Diallo A, Sellier N.

Radiology. 2016 Aug;280(2):611-21. doi: 10.1148/radiol.2016150743. Epub 2016 Mar 24. Erratum in: Radiology. 2016 Sep;280(3):981.

PMID:
27010381
33.

Percutaneous Treatment of Localized Infiltrative Hepatocellular Carcinoma Developing on Cirrhosis.

Nault JC, Nkontchou G, Nahon P, Grando V, Bourcier V, Barge S, Ziol M, Sellier N, Ganne-Carrie N, Seror O.

Ann Surg Oncol. 2016 Jun;23(6):1906-15. doi: 10.1245/s10434-015-5064-4. Epub 2016 Jan 5.

PMID:
26732275
34.

Prevalence and clinical significance of nodular regenerative hyperplasia in liver biopsies.

Barge S, Grando V, Nault JC, Broudin C, Beaugrand M, Ganne-Carrié N, Roulot D, Ziol M.

Liver Int. 2016 Jul;36(7):1059-66. doi: 10.1111/liv.12974. Epub 2015 Oct 19.

PMID:
26415006
35.

Hepatic nodular lymphoid lesion with increased IgG4-positive plasma cells associated with primary biliary cirrhosis: a report of two cases.

Calvo J, Carbonell N, Scatton O, Marzac C, Ganne-Carrie N, Wendum D.

Virchows Arch. 2015 Nov;467(5):613-7. doi: 10.1007/s00428-015-1841-5. Epub 2015 Sep 10.

PMID:
26358058
36.

Combining Data From Liver Disease Scoring Systems Better Predicts Outcomes of Patients With Alcoholic Hepatitis.

Louvet A, Labreuche J, Artru F, Boursier J, Kim DJ, O'Grady J, Trépo E, Nahon P, Ganne-Carrié N, Naveau S, Diaz E, Gustot T, Lassailly G, Cannesson-Leroy A, Canva-Delcambre V, Dharancy S, Park SH, Moreno C, Morgan TR, Duhamel A, Mathurin P.

Gastroenterology. 2015 Aug;149(2):398-406.e8; quiz e16-7. doi: 10.1053/j.gastro.2015.04.044. Epub 2015 Apr 29.

PMID:
25935634
37.

Genetic risk markers for hepatocellular carcinoma in patients with alcoholic liver disease.

Nahon P, Sutton A, Ziol M, Zucman-Rossi J, Trinchet JC, Ganne-Carrié N.

Hepat Oncol. 2015 Jan;2(1):63-78. doi: 10.2217/hep.14.26. Epub 2015 Jan 12. Review.

38.

Predicting recurrence following radiofrequency percutaneous ablation for hepatocellular carcinoma.

Ganne-Carrié N, Nault JC, Ziol M, N'Kontchou G, Nahon P, Grando V, Bourcier V, Barge S, Beaugrand M, Trinchet JC, Seror O.

Hepat Oncol. 2014 Oct;1(4):395-408. doi: 10.2217/hep.14.22. Epub 2014 Dec 11. Review.

39.

Impact of cytokine gene variants on the prediction and prognosis of hepatocellular carcinoma in patients with cirrhosis.

Tarhuni A, Guyot E, Rufat P, Sutton A, Bourcier V, Grando V, Ganne-Carrié N, Ziol M, Charnaux N, Beaugrand M, Moreau R, Trinchet JC, Mansouri A, Nahon P.

J Hepatol. 2014 Aug;61(2):342-50. doi: 10.1016/j.jhep.2014.04.011. Epub 2014 Apr 18.

PMID:
24751829
40.

Hepatocellular carcinoma screening in patients with compensated hepatitis C virus (HCV)-related cirrhosis aware of their HCV status improves survival: a modeling approach.

Mourad A, Deuffic-Burban S, Ganne-Carrié N, Renaut-Vantroys T, Rosa I, Bouvier AM, Launoy G, Cattan S, Louvet A, Dharancy S, Trinchet JC, Yazdanpanah Y, Mathurin P.

Hepatology. 2014 Apr;59(4):1471-81. doi: 10.1002/hep.26944. Epub 2014 Feb 25.

PMID:
24677195
41.

ESM-1 expression in stromal cells is predictive of recurrence after radiofrequency ablation in early hepatocellular carcinoma.

Ziol M, Sutton A, Calderaro J, Barget N, Aout M, Leroy V, Blanc JF, Sturm N, Bioulac-Sage P, Nahon P, Nault JC, Charnaux N, N'kontchou G, Trinchet JC, Delehedde M, Seror O, Beaugrand M, Vicaut E, Ganne-Carrié N.

J Hepatol. 2013 Dec;59(6):1264-70. doi: 10.1016/j.jhep.2013.07.030. Epub 2013 Aug 6.

PMID:
23928407
42.

Serum proteoglycans as prognostic biomarkers of hepatocellular carcinoma in patients with alcoholic cirrhosis.

Nault JC, Guyot E, Laguillier C, Chevret S, Ganne-Carrie N, N'Kontchou G, Beaugrand M, Seror O, Trinchet JC, Coelho J, Lasalle P, Charnaux N, Delehedde M, Sutton A, Nahon P.

Cancer Epidemiol Biomarkers Prev. 2013 Aug;22(8):1343-52. doi: 10.1158/1055-9965.EPI-13-0179. Epub 2013 Jun 18.

43.

[Screening of hepatocellular carcinoma and surveillance of patients with cirrhosis: a public health issue].

Trinchet JC, Nahon P, Ganne-Carrie N.

Rev Prat. 2013 Feb;63(2):222-5. Review. French.

PMID:
23513790
44.

Peripheral intrahepatic cholangiocarcinoma occurring in patients without cirrhosis or chronic bile duct diseases: epidemiology and histopathology of distant nontumoral liver in 57 White patients.

Nkontchou G, Tran Van Nhieu J, Ziol M, Tengher I, Mahmoudi A, Roulot D, Bourcier V, Ganne Carrie N, Grando-Lemaire V, Trinchet JC, Cherqui D, Beaugrand M.

Eur J Gastroenterol Hepatol. 2013 Jan;25(1):94-8. doi: 10.1097/MEG.0b013e328357cdd7.

PMID:
23085575
45.

PNPLA3 rs738409, hepatocellular carcinoma occurrence and risk model prediction in patients with cirrhosis.

Guyot E, Sutton A, Rufat P, Laguillier C, Mansouri A, Moreau R, Ganne-Carrié N, Beaugrand M, Charnaux N, Trinchet JC, Nahon P.

J Hepatol. 2013 Feb;58(2):312-8. doi: 10.1016/j.jhep.2012.09.036. Epub 2012 Oct 13.

PMID:
23069476
46.

Effect of long-term propranolol treatment on hepatocellular carcinoma incidence in patients with HCV-associated cirrhosis.

Nkontchou G, Aout M, Mahmoudi A, Roulot D, Bourcier V, Grando-Lemaire V, Ganne-Carrie N, Trinchet JC, Vicaut E, Beaugrand M.

Cancer Prev Res (Phila). 2012 Aug;5(8):1007-14. doi: 10.1158/1940-6207.CAPR-11-0450. Epub 2012 Apr 23.

47.

PNPLA3 (rs738409 C>G) is a common risk variant associated with hepatocellular carcinoma in alcoholic cirrhosis.

Trepo E, Guyot E, Ganne-Carrie N, Degre D, Gustot T, Franchimont D, Sutton A, Nahon P, Moreno C.

Hepatology. 2012 Apr;55(4):1307-8. doi: 10.1002/hep.25518. No abstract available.

PMID:
22162034
48.

HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis.

Nkontchou G, Ziol M, Aout M, Lhabadie M, Baazia Y, Mahmoudi A, Roulot D, Ganne-Carrie N, Grando-Lemaire V, Trinchet JC, Gordien E, Vicaut E, Baghad I, Beaugrand M.

J Viral Hepat. 2011 Oct;18(10):e516-22. doi: 10.1111/j.1365-2893.2011.01441.x.

PMID:
21914071
49.

A variant in myeloperoxidase promoter hastens the emergence of hepatocellular carcinoma in patients with HCV-related cirrhosis.

Nahon P, Sutton A, Rufat P, Charnaux N, Mansouri A, Moreau R, Ganne-Carrié N, Grando-Lemaire V, N'Kontchou G, Trinchet JC, Pessayre D, Beaugrand M.

J Hepatol. 2012 Feb;56(2):426-32. doi: 10.1016/j.jhep.2011.08.010. Epub 2011 Sep 8.

PMID:
21907168
50.

Bone mineral density assessed by dual-energy X-ray absorptiometry in patients with viral or alcoholic compensated cirrhosis. A prospective study.

Mahmoudi A, Sellier N, Reboul-Marty J, Chalès G, Lalatonne Y, Bourcier V, Grando V, Barget N, Beaugrand M, Trinchet JC, Ganne-Carrié N.

Clin Res Hepatol Gastroenterol. 2011 Nov;35(11):731-7. doi: 10.1016/j.clinre.2011.07.009. Epub 2011 Aug 27.

PMID:
21873139

Supplemental Content

Loading ...
Support Center